[32] Aguiar, M. (2018). Dengue vaccination: a more ethical approach is needed. The Lancet, 391(10132):1769-1770.

[31] Aguiar, M. and Stollenwerk, N. (2018). Dengvaxia: age as surrogate for serostatus. The Lancet Infectious Diseases. 18(3): 245.

[30] Aguiar, M. and Stollenwerk, N. (2018). Dengvaxia efficacy dependency on serostatus: a closer look at more recent data. Clinical Infectious Diseases 66(4): 641-642.

[29] Aguiar, M. and Stollenwerk, N. (2017). Mathematical models of dengue fever epidemiology: multi-strain dynamics, immunological aspects associated to disease severity and vaccines. Communication in Biomathematical Sciences 1(1): 1-12.

[28] Maíra Aguiar, Scott B. Halstead and Nico Stollenwerk. (2017). Consider stopping dengvaxia administration without immunological screening. Expert Review of Vaccines 16 (4): 301-302.

[27] Stollenwerk, N., Sommer, P.F., Kooi, B.W., Mateus, L., Ghaffari, P., Aguiar, M. (2016). Hopf and torus bifurcations, torus destruction and chaos in population biology. Ecological Complexity, 30: 91-99.

[26] Pennekamp, F., Adamson, M.W., Petchey, O.L., Poggialle, J.C., Aguiar, M., Kooi, B.W., Botkin, D., DeAngelis, D.L. (2016). The practice of prediction: what can ecologists learn from applied, ecology-related fields? Ecological Complexity, 32, 156-167.

[25] Aguiar, M., Stollenwerk, N., & Halstead, S.B. (2016). Modeling the impact of the newly licensed dengue vaccine in endemic countries. PLoS Neglected Tropical Diseases, 10(12): e0005179.